NASDAQ:XNCRXencor Stock Price, Forecast & News

Xencor's stock was trading at $28.12 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, XNCR stock has increased by 17.1% and is now trading at $32.92.
View which stocks have been most impacted by COVID-19.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xencor in the last year. There are currently 2 sell ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Xencor.

Xencor is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Xencor.

Xencor Inc (NASDAQ:XNCR) announced its quarterly earnings results on Tuesday, August, 4th. The biopharmaceutical company reported ($0.61) earnings per share for the quarter, missing the consensus estimate of ($0.56) by $0.05. Xencor had a negative return on equity of 13.56% and a negative net margin of 113.40%.
View Xencor's earnings history.

8 brokers have issued 1 year target prices for Xencor's stock. Their forecasts range from $21.00 to $52.00. On average, they anticipate Xencor's share price to reach $41.00 in the next year. This suggests a possible upside of 24.5% from the stock's current price.
View analysts' price targets for Xencor.

Media coverage about XNCR stock has trended very positive this week, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Xencor earned a news sentiment score of 4.0 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term.
View the latest news about Xencor.

Xencor saw a increase in short interest in the month of June. As of June 30th, there was short interest totaling 3,840,000 shares, an increase of 26.3% from the June 15th total of 3,040,000 shares. Based on an average daily volume of 538,000 shares, the short-interest ratio is currently 7.1 days.
View Xencor's Short Interest.

Some companies that are related to Xencor include Perrigo (PRGO), Emergent Biosolutions (EBS), Jazz Pharmaceuticals (JAZZ), ACADIA Pharmaceuticals (ACAD), Bausch Health Companies (BHC), Mirati Therapeutics (MRTX), Myokardia (MYOK), Ultragenyx Pharmaceutical (RARE), United Therapeutics (UTHR), Zai Lab (ZLAB), HUTCHISON CHINA/S (HCM), Schrodinger (SDGR), Allakos (ALLK), Blueprint Medicines (BPMC) and Arrowhead Pharmaceuticals (ARWR).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Xencor investors own include Intelsat (I), Bank of America (BAC), Cypress Semiconductor (CY), AbbVie (ABBV), Apollo Global Management (APO), NVIDIA (NVDA), AMC Entertainment (AMC), Exelixis (EXEL), Fossil Group (FOSL) and Intel (INTC).

Xencor trades on the NASDAQ under the ticker symbol "XNCR."

Xencor's stock is owned by a variety of institutional and retail investors. Top institutional investors include FMR LLC (14.94%), Vanguard Group Inc. (10.08%), BVF Inc. IL (3.61%), Goldman Sachs Group Inc. (1.58%), Bank of New York Mellon Corp (0.98%) and Candriam Luxembourg S.C.A. (0.81%). Company insiders that own Xencor stock include John J Kuch, John R Desjarlais, John S Stafford III, Paul A Foster and Ronin Capital, Llc.
View institutional ownership trends for Xencor.

XNCR stock was sold by a variety of institutional investors in the last quarter, including Federated Hermes Inc., UBS Group AG, Rhenman & Partners Asset Management AB, WINTON GROUP Ltd, Mutual of America Capital Management LLC, Barclays PLC, Smith Asset Management Group LP, and Texas Permanent School Fund. Company insiders that have sold Xencor company stock in the last year include John J Kuch, John R Desjarlais, John S Stafford III, and Ronin Capital, Llc.
View insider buying and selling activity for Xencor.

XNCR stock was acquired by a variety of institutional investors in the last quarter, including BVF Inc. IL, Vanguard Group Inc., Goldman Sachs Group Inc., Candriam Luxembourg S.C.A., Man Group plc, Marshall Wace North America L.P., Prudential Financial Inc., and Marshall Wace LLP.
View insider buying and selling activity for Xencor.

Shares of XNCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of XNCR stock can currently be purchased for approximately $32.92.

Xencor has a market capitalization of $1.88 billion and generates $156.70 million in revenue each year. The biopharmaceutical company earns $26.88 million in net income (profit) each year or $0.46 on an earnings per share basis. Xencor employs 156 workers across the globe.

The official website for Xencor is www.xencor.com.

Xencor's mailing address is 111 WEST LEMON AVENUE, MONROVIA CA, 91016. The biopharmaceutical company can be reached via phone at 626-305-5900 or via email at [email protected]